Details of the Drug Reposition

General Information of This Drug (ID: DMQ9KZW)

Drug Name
Biomed 101   DMQ9KZW
Synonyms
BioMed 101; SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Kidney cancer DISBIPKM 2C90.0 Phase 1 [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Inflammatory bowel disease DISGN23E DD72 Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00004890)Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer in National Cancer Institute (NCI).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6156).